Perioperative clopidogrel and postoperative events after hip and knee arthroplasties

Clinical Orthopaedics and Related Research

Volumn 470, Issue 5, 2012, Pages 1436-1441

  Nandi, Sumon ^a   Aghazadeh, Mehran ^a   Talmo, Carl ^a   Robbins, Claire ^a   Bono, James ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLOPIDOGREL;

AGED; ANTIBIOTIC THERAPY; ARTICLE; CELLULITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SAFETY; FEMALE; HEMATOMA; HIP ARTHROPLASTY; HOSPITAL READMISSION; HUMAN; KNEE ARTHROPLASTY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; POSTOPERATIVE HEMORRHAGE; PREDICTION; PRIORITY JOURNAL; REOPERATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SURGICAL INFECTION; SURGICAL MORTALITY; SURGICAL RISK; WOUND DRAINAGE;

EID: 84859872582     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1007/s11999-012-2306-7     Document Type: Article

References (21)

1. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership (August 2010). PLAVIX (clopidogrel bisulfate): help prevent clot formation for heart attack, stroke, or PAD patients. PLAVIX (clopidogrel bisulfate) tablets prescribing information. Available at: www.plavix.com. Accessed October 15, 2010.
2. Butler MJ, Eccleston D, Clark DJ, Ajani AE, Andrianopoulos N, Brennan A, New G, Black A, Szto G, Reid CM, Yan BP, Shaw JA, Dart AM, Duffy SJ; Melbourne Interventional Group. The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drugeluting stents. Am Heart J. 2009;157:899-907.
3. Dorr LD, Gendelman V, Maheshwari AV, Boutary M, Wan Z, Long WT. Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment. J Bone Joint Surg Am. 2007;89:2648-2657. (Pubitemid 350230619)
4. Dripps RD. New classification of physical status. Anesthesiology. 1963;24:111.
5. Harty JA, McKenna P, Moloney D, D'Souza L, Masterson E. Anti-platelet agents and surgical delay in elderly patients with hip fractures. J Orthop Surg (Hong Kong). 2007;15:270-272.
6. Inman DS, Michla Y, Partington PF. Perioperative management of trauma patients admitted on clopidogrel (Plavix): a survey of orthopaedic departments across the United Kingdom. Injury. 2007;38:625-630. (Pubitemid 46653942)
7. Koch CG, Li L, Duncan AI, Mihaljevic T, Cosgrove DM, Loop FD, Starr NJ, Blackstone EH. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med. 2006;34:1608-1616. (Pubitemid 43810038)
8. Kurtz S, Mowat F, Ong K, Chan N, Lau E, Halpern M. Prevalance of primary and revision total hip and knee arthroplasty in the United States from 1990 through 2002. J Bone Joint Surg Am. 2005;87:1487-1497. (Pubitemid 40917748)
9. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007; 89:780-785. (Pubitemid 46564282)
10. Kurtz SM, Lau E, Ong K, Zhao K, Kelly M, Bozic KJ. Future young patient demand for primary and revision joint replacement: national projections from 2010 to 2030. Clin Orthop Relat Res. 2009;467:2606-2612.
11. Kurtz SM, Ong KL, Schmier J, Zhao K, Mowat F, Lau E. Primary and revision arthroplasty surgery caseloads in the United States from 1990 to 2004. J Arthroplasty. 2009;24:195-203.
12. Lavelle WF, Demers Lavelle EA, Uhl R. Operative delay for orthopedic patients on clopidogrel (Plavix): a complete lack of consensus. J Trauma. 2008;64:996-1000. (Pubitemid 351521891)
13. Mahomed NN, Barrett JA, Katz JN, Phillips CB, Losina E, Lew RA, Guadagnoli E, Harris WH, Poss R, Baron JA. Rates and outcomes of primary and revision total hip replacement in the United States Medicare population. J Bone Joint Surg Am. 2003; 85:27-32. (Pubitemid 36537969)
14. Mahoney EM, Wang K, Keo HH, Duval S, Smolderen KG, Cohen DJ, Steg G, Bhatt DL, Hirsch AT; Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Vascular hopitalization rates and costs in patients with peripheral artery disease in the United States. Circ Cardiovasc Qual Outcomes. 2010;3:642-651.
15. Memtsoudis SG, Ma Y, Gonzalez Della Valle A, Besculides MC, Gaber LK, Koulouvaris P, Liu SS. Demographics, outcomes and risk factors for adverse events associated with primary and revision total hip arthroplasties in the United States. Am J Orthop (Belle Mead NJ). 2010;39:E72-E77.
16. Nydick JA, Farrell ED, Marcantonio AJ, Hume EL, Marburger R, Ostrum RF. The use of clopidogrel (Plavix) in patients undergoing nonelective orthopaedic surgery. J Orthop Trauma. 2010; 24:383-386.
17. Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, Moliterno DJ, Linblad L, Pieper K, Topol EJ, Stamler JS, Califf RM. Relationship of blood transfusion and linical outcomes in patients with acute coronary syndromes. JAMA. 2004;292:1555-1562. (Pubitemid 39314961)
18. Santaguida PL, Hawker GA, Hudak PL, Glazier R, Mahomed NN, Kreder HJ, Coyte PC, Wright JG. Patient characteristics affecting the prognosis of total hip and knee joint arthroplasty: a systematic review. Can J Surg. 2008;51:428-436.
19. Tsai TT, Ho PM, Xu S, Powers JD, Carroll NM, Shetterly SM, Maddox TM, Rumsfeld JS, Margolis K, Go AS, Magid DJ. Increased risk of bleeding in patients on clopidogrel therapy after drug-eluting stents implantation: insights from the HMO Research Network-Stent Registry (HMORN-stent). Circ Cardiovasc Interv. 2010;3:230-235.
20. Viera AJ, Sheridan SL. Global risk of coronary heart disease: assessment and application. Am Fam Physician. 2010;82:265-274.
21. Zhan C, Kaczmarek R, Loyo-Berrios N, Sangl J, Bright RA. Incidence and short-term outcomes of primary and revision hip replacement in the United States. J Bone Joint Surg Am. 2007; 89:526-533. (Pubitemid 46365352)